Artiva Scraps Lead Candidate AlloNK, Slashes Workforce, Hires Adviser to Explore Options — Update

What happened

Artiva Biotherapeutics is ending work on its lead drug AlloNK, including a planned Phase 3 study, after longer-term data showed responses were not durable enough. Two Phase 2a patients died. The company is cutting 94% of its workforce and exploring options.

Confirmed

Global impact / market context

Scrapping the lead drug removes the main reason investors owned the shares, and the 94% staff cut leaves little capacity to run trials. Hiring an adviser to explore options points to a sale or wind-down, so shareholders face an outcome decided by negotiation rather than drug results.

Analyst inference

The stock fell 31% to $4.28 before the open, against a market value of roughly $300 million, showing investors already assumed AlloNK would fail. With no program advancing and most staff gone, the company's value now rests on its remaining cash and any sale price.

Analyst inference

What to watch

1. Artiva had 104 full-time employees at the end of 2025 and is cutting 94% of them, leaving about six staff, which means almost no internal ability to run new trials. Confirmed
2. The company has hired an adviser to explore options, which could mean a sale, merger, or wind-down. Watch for a concrete transaction or a stated plan for returning cash to shareholders. Proposed
3. Watch the remaining cash and the costs of the wind-down, because those determine what is left for shareholders. Also watch whether the U.S. Food and Drug Administration pause on the Phase 2a study is formally lifted or left in place. Analyst inference

Evidence

• Original source link unavailable